Piramal Pharma raises FY27 growth outlook on strong Q2 performance

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDF Explain this filing

PPLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+15.4%Reaction day

₹199.75

prior close

₹214.10

announcement price

After-mkt

timing

Nifty Smallcap 250marketpendingvs market: pending

Pharmaceuticals peers, median of 170sector+0.6%+14.9% vs sector

On the reaction day the stock moved 14.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.8

10m

+3.9

15m

+2.8

30m

+4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+15.4pendingpending+0.6+14.9

Next day

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Piramal Pharma's Q2 FY27 revenue was ₹2,617 crore, up 28%, while EBITDA rose 72% to ₹385 crore and margin reached 14.7% from 11%. H1 revenue rose 23% to ₹4,887 crore; EBITDA rose 72% to ₹669 crore, with profit after tax of ₹5 crore versus a ₹99 crore loss. Management raised FY27 revenue growth guidance to 19-20% with higher profitability, citing strong order inflows, 22 new customers and better capacity use. Net debt rose to ₹4,859 crore.

Likely market impact

Positive sentiment is likely from stronger growth, margins and raised guidance, but watch order conversion and rising net debt.